Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F. Pean E, et al. Among authors: abadie e. Oncologist. 2012;17(4):543-9. doi: 10.1634/theoncologist.2011-0364. Epub 2012 Apr 3. Oncologist. 2012. PMID: 22477727 Free PMC article. Review.
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F. Matt P, et al. Among authors: abadie e. Oncologist. 2011;16(10):1451-7. doi: 10.1634/theoncologist.2011-0224. Epub 2011 Sep 30. Oncologist. 2011. PMID: 21963999 Free PMC article. Review.
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M, Borregaard J, Ersbøll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F. Nieto M, et al. Among authors: abadie e. Clin Cancer Res. 2011 Nov 1;17(21):6608-14. doi: 10.1158/1078-0432.CCR-11-1734. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976546 Review.
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F. Pean E, et al. Among authors: abadie e. Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24. Clin Cancer Res. 2012. PMID: 22829199
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Gravanis I, Ersbøll J, Skovlund E, Abadie E, Marty M, Pignatti F. Gravanis I, et al. Among authors: abadie e. Oncologist. 2010;15(12):1335-43. doi: 10.1634/theoncologist.2010-0255. Epub 2010 Dec 14. Oncologist. 2010. PMID: 21156732 Free PMC article.
The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M, Calvo G, Hudson I, Feldschreiber P, Brown D, Lee CC, Lay G, Valeri A, Abadie E, Thomas A, Pignatti F. Nieto M, et al. Among authors: abadie e. Haematologica. 2011 Sep;96(9):e33-40. doi: 10.3324/haematol.2011.048819. Epub 2011 Jun 28. Haematologica. 2011. PMID: 21712542 Free PMC article. Review.
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F. Hanaizi Z, et al. Among authors: abadie e. Eur J Cancer. 2012 Jan;48(2):237-42. doi: 10.1016/j.ejca.2011.09.018. Epub 2011 Oct 24. Eur J Cancer. 2012. PMID: 22030452 Review.
Regulators, payers, and prescribers: can we fill the gaps?
Pignatti F, Luria X, Abadie E, Eichler HG. Pignatti F, et al. Among authors: abadie e. Lancet Oncol. 2011 Sep;12(10):930-1. doi: 10.1016/S1470-2045(11)70229-7. Lancet Oncol. 2011. PMID: 21958501 No abstract available.
Rosiglitazone: a European regulatory perspective.
Blind E, Dunder K, de Graeff PA, Abadie E. Blind E, et al. Among authors: abadie e. Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14. Diabetologia. 2011. PMID: 21153629 No abstract available.
Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L. Isaac M, et al. Among authors: abadie e. Eur Neuropsychopharmacol. 2011 Nov;21(11):781-8. doi: 10.1016/j.euroneuro.2011.08.003. Epub 2011 Sep 7. Eur Neuropsychopharmacol. 2011. PMID: 21903360
124 results